1.	Phase III Randomized Study of Polyvalent Antigen-KLH Conjugate Vaccine in Combination With OPT-821 Versus OPT-821 Alone in Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer in Second or Third Complete Clinical Remission Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-OVM0703, GOG OVM0703, OVM0703, NCT00693342
2.	Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: 05-075, NCT00911560
3.	Phase II Randomized Study of Immunological Adjuvant OPT-821 With Versus Without Polyvalent Antigen-KLH Conjugate Vaccine in Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer in Second or Third Complete Clinical Remission Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0255, GOG-0255, NCT00857545
4.	Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MV-0109DP001, NCT01141491
5.	Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects Phase: Phase II Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: OPT-822-001, NCT01516307
6.	Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 08-095, NCT01349647